相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Synergistic antitumor effect of anti-PD-L1 combined with oxaliplatin on a mouse tumor model
Soheila Golchin et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
Photothermal therapy mediated by phase-transformation nanoparticles facilitates delivery of anti-PD1 antibody and synergizes with antitumor immunotherapy for melanoma
Ni Zhang et al.
JOURNAL OF CONTROLLED RELEASE (2019)
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, efficacy, and Limitations
Judith A. Seidel et al.
FRONTIERS IN ONCOLOGY (2018)
Targeting antigen-presenting cells by anti-PD-1 nanoparticles augments antitumor immunity
Farideh Ordikhani et al.
JCI INSIGHT (2018)
The importance of correctly timing cancer immunotherapy
Elham Beyranvand Nejad et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2017)
Improved tumor accumulation and therapeutic efficacy of CTLA-4-blocking antibody using liposome-encapsulated antibody: In vitro and in vivo studies
Amin Reza Nikpoor et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2017)
Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
Vivek Kumar et al.
FRONTIERS IN PHARMACOLOGY (2017)
Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth
Karla Parra et al.
BRITISH JOURNAL OF CANCER (2017)
Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy
Christina Pfirschke et al.
IMMUNITY (2016)
5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers
Lauren Van der Kraak et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis
Anne Bertrand et al.
BMC MEDICINE (2015)
Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
Amita Patnaik et al.
CLINICAL CANCER RESEARCH (2015)
Nanoliposome-mediated targeting of antibodies to tumors: IVIG antibodies as a model
Amin Reza Nikpoor et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2015)
Concepts and mechanisms underlying chemotherapy induced immunogenic cell death: Impact on clinical studies and considerations for combined therapies
Simon Gebremeskel et al.
ONCOTARGET (2015)
Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma
Rafael Winograd et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Doxil Synergizes with Cancer Immunotherapies to Enhance Antitumor Responses in Syngeneic Mouse Models
Jonathan Rios-Doria et al.
NEOPLASIA (2015)
Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists
T. Yamazaki et al.
CELL DEATH AND DIFFERENTIATION (2014)
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma
Tyler R. Simpson et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
CTLA-4 Blockade Expands Infiltrating T Cells and Inhibits Cancer Cell Repopulation during the Intervals of Chemotherapy in Murine Mesothelioma
Licun Wu et al.
MOLECULAR CANCER THERAPEUTICS (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
The safety and side effects of monoclonal antibodies
Trevor T. Hansel et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Immunological aspects of cancer chemotherapy
Laurence Zitvogel et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Review: Anti-CTLA-4 antibody ipilimumab: Case studies of clinical response and immune-related adverse events
Jeffrey Weber
ONCOLOGIST (2007)
Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses
RPM Sutmuller et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2001)
分享论文
